Looking forward to results from the prototype later this year. That will be huge if all goes as planned. I backed off my position a little. My thinking was that there will be opportunities to pick it up cheap on dips before the actual instrument has been proven. We'll see.
I've been buying Covalon this past week. I think IV clear and Surgiclear will be big with Molnlycke. Their sales have been strong right out of the gate and COV should get a significant cut of it with the supply agreement. And with the 15MM in tax losses off the balance sheet, COV is reasonbly priced even by value investor standards.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.